Valneva USA, Inc. Advancing vaccines for better lives.

• Led service delivery team to the successful delivery of hundreds of genomic projects per year • Leveraged project management software to implement a portfolio monitoring system resulting in 20% improvement in bioinformatic reporting turnaround time. • Consulted with sponsors, CROs, and other vendors to create Scopes of Work (SOW) and Data Transfer Agreements (DTA) aligning with study goals and clinical regulations. • Onboarded a ticket-based system to simplify client project communications and improve email response times by 15%. • Collaborated with quality and laboratory teams to align processes with GCP compliance. • Conducted clinical data review, transfer, and reconciliation tasks. • Implemented automated customer satisfaction (CSAT) surveys and monitored responses to identify targets for continual process improvement leading to increased customer success.

𝘐𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘏𝘦𝘢𝘭𝘵𝘩 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴. MaximBio's comprehensive in-house capabilities provide you a world-class experience and confidence in our ability to keep costs down and deliver your products in time. At MaximBio, our team of dedicated professionals with over 25 years of expertise work to create a custom-fit, full service program in state-of-the-art facilities to meet all your needs and specifications: • FDA cGMP Registered for manufacture and distribution of medical devices • Compliant with 21 CFR Part 820 for medical devices • ISO 13485:2016 Certified for manufacturing and packaging of medical devices

ExeGi Pharma is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. Our team leverages the field of microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a variety of unmet medical needs for both humans and veterinary applications. Makers of Visbiome and Visbiome Vet high potency probiotics.

Imagilin® Technology, LLC is a biotechnology company based in Frederick, Maryland, USA. Since 2003, we have been committed to developing innovative technologies and producing nutraceutical products with an emphasis on the company's patented plant-based probiotics to enhance and support human and animal health. We are rapidly expanding throughout the United States and Asian markets with comprehensive involvement in basic research, as well as clinical studies worldwide for all our products. We are dedicated to revolutionizing plant-based products that ensure ethical performance and provide greater value to all of our members and the environment. We collaborate with renowned institutions worldwide to ensure the effectiveness and quality of our products. Imagilin® Technology, LLC is well recognized for its continuous innovation in developing cleaner, healthier supplements that are safe,effective, and held to a higher standard. Currently, our probiotic technology platform and intellectual properties are protected by 8 issued patents and several pending patents in order to support our nutraceutical developments. We market the patented probiotic strain Pediococcus Acidilactici NRRL B-50517 to companies seeking to incorporate this natural ingredient into their dietary supplements and food products. Finished probiotic goods are also readily available to the public as dietary supplements for humans and animals through a channel of retail stores and websites. Find out where you can purchase: https://www.imagilin.com/where-to-buy.

AMIVAS is a US, Australian, and European joint venture focused on the development and commercialization of therapeutics for the treatment of life-threatening diseases with offices in the US, Australia and Ireland. AMIVAS manufactures in North America and our partners in Canada, USA and Europe package and supply our product to hospitals and patients in need. AMIVAS’ vision was formed in response to the urgent need for a US and Europe- based firm to assume responsibility for the manufacture and distribution of Artesunate, for the treatment of severe malaria after quinidine gluconate was discontinued in 2019. With the US Food and Drug Administration (FDA) approval of its first commercial product on May 26, 2020, AMIVAS is proud to join the global effort to fight and eradicate malaria.